Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
HemaSphere · 2024-01 · 8 (1)
DOI: 10.1002/hem3.33 ↗At a glance
Kohortenstudie in HemaSphere, published online on 2024-01-26. Written by Hyungwoo Cho and 17 co-authors. Institution: Department of Oncology Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea. Cited 6 times so far (Crossref); 5 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Multiple myeloma (MM) is a plasma cell neoplasm with significant variability in survival outcomes due to its complex and heterogeneous nature.Therefore, the development of an accurate prognostic model is crucial in clinical practice to guide treatment decisions, predict disease outcomes, and inform patients.Recently, the European Myeloma Network (EMN) developed and validated the second revision of the International Staging System (R2-ISS) using a large number of patients with newly diagnosed MM. 1 The R2-ISS incorporates several risk factors, including the ISS, serum lactate dehydrogenase (LDH), del(17p), t(4;14), and 1q gain/amplification.Each risk feature is assigned a specific value (ISS II: 1; ISS III: 1.5; del[17p]: 1; elevated LDH: 1; t[4;14]: 1; and 1q gain/amplification: 0.5 points), and patients are classified into four risk groups based on the cumulative score: low (R2-ISS I, 0 points), low-intermediate (R2-ISS II, 0.5-1 points), intermediate-high (R2-ISS III, 1.5-2.5 points), and high (R2-ISS IV, 3-5 points).The R2-ISS has demonstrated enhanced discriminative capability, particularly for patients with intermediate risk, compared to the original Revised ISS (R-ISS).Yet, it is important to note that the development and validation of the R2-ISS were primarily based on patients enrolled in clinical trials, which often exclude individuals with comorbidities and poor performance status.Thus, the objective of our study (KMM 2202) is to validate the R2-ISS in an independent cohort of patients from real-world clinical practice and compare its performance to that of the R-ISS.We collected data from newly diagnosed MM patients treated between January 2010 and July 2019 at 13 hospitals participating in the Korean Multiple Myeloma Working Party in South Korea.All patients received either an immunomodulatory drug (IMiD) or a proteasome inhibitor (PI) as part of their first-line treatment.Only the patients with complete information on both R2-ISS and R-ISS were included in the study.In situ hybridization fluorescence in situ hybridization (iFISH) studies were performed on sorted or immunologically recognized plasma cells, following the specific iFISH methods of each institution.The study received approval from the institutional review boards of all participating institutions.
Authors and institutions
- Department of Oncology Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea.
- Department of Medicine, Division of Hematology/Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea.
- Department of Hematology-Oncology, Chonnam National University Hwasun Hospital Chonnam National University Medical School Hwasun South Korea.
- Department of Hematology-Oncology, School of Medicine, Kyungpook National University Hospital Kyungpook National University Daegu South Korea.
- Department of Internal Medicine Kosin University College of Medicine Busan South Korea.
- Department of Internal Medicine Korea University College of Medicine Seoul South Korea.
Cite
APA
Cho, H., Kim, K., Yoon, S. E., Jung, S. H., Lee, J. J., Moon, J. H., Cho, H. J., Lee, H. S., Kang, K. W., Kim, S. Y., Eom, H. S., Mun, Y. C., Park, Y. H., Yoon, S. S., Do, Y. R., Lee, W. S., Min, C. K., & Yoon, D. H. (2024). Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202). HemaSphere, 8(1). https://doi.org/10.1002/hem3.33
Vancouver
Cho H, Kim K, Yoon SE, Jung SH, Lee JJ, Moon JH, et al. Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202). HemaSphere. 2024;8(1). doi:10.1002/hem3.33
BibTeX
@article{Cho2024,
author = {Cho, Hyungwoo and Kim, Kihyun and Yoon, Sang Eun and Jung, Sung-Hoon and Lee, Je-Jung and Moon, Joon Ho and Cho, Hee Jeong and Lee, Ho Sup and Kang, Ka-Won and Kim, Sung-Yong and Eom, Hyeon-Seok and Mun, Yeung-Chul and Park, Young Hoon and Yoon, Sung-Soo and Do, Young Rok and Lee, Won Sik and Min, Chang-Ki and Yoon, Dok Hyun},
title = {Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)},
journal = {HemaSphere},
year = {2024},
volume = {8},
number = {1},
doi = {10.1002/hem3.33}
}
EUVIMED